加载中
NASDAQHealthcareBiotechnology
最新数据
US$24.86
−US$0.06 · -0.24%
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
收盘时
US$24.86
−US$0.06 · -0.24%
盘后
US$24.86
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
日内区间
当前US$24.86
52周区间
当前US$24.86
盘中时间采用ET。市场数据可能有所延迟。
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
日内区间
当前US$24.86
52周区间
当前US$24.86
| 项目（USD） | 2025财年 |
|---|---|
| 销货成本 | 61.2万 USD |
| 毛利 | −61.2万 USD |
| 研究与开发 | 2864万 USD |
| 销售、一般及管理费用 | 1219.7万 USD |
| 营业费用 | 4083.7万 USD |
| 利息收入 | 310.6万 USD |
| 折旧和摊销 | 61.2万 USD |
| 营业利润 | −4144.9万 USD |
| 净利润 | −3986.9万 USD |
公司数据更新于 2026年10月13日。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI827.51万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM615.8万0.01%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF295.59万0.00%954亿 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO166.09万0.01%180亿 USD0.06%US$112.27-0.35%
iShares Russell 2000 Growth ETFIWO147.46万0.01%139.17亿 USD0.24%US$353.71-0.86%
ALPS Medical Breakthroughs ETFSBIO105.83万0.55%1.91亿 USD0.50%US$53.85-2.16%
Avantis Emerging Markets Equity ETFAVEM104.51万—284.09亿 USD0.33%US$93.27-0.89%
Schwab U.S. Small-Cap ETFSCHA88.03万0.00%218.24亿 USD0.03%US$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOALPS Medical Breakthroughs ETFSBIOAvantis Emerging Markets Equity ETFAVEMSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
